Advertisement
Screener

NeoGenomics, Inc. (NEO) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

NeoGenomics, Inc. Increase Decrease In Operating Lease Liability

NeoGenomics, Inc. (NEO) reported Increase Decrease In Operating Lease Liability of -$2.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-28

  • NeoGenomics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.30M, a 243.96% decline year-over-year.
  • NeoGenomics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.30M.
  • NeoGenomics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.23M.
  • NeoGenomics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$795.00K.
  • NeoGenomics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$2.21M.
  • NeoGenomics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$6.00M.
  • NeoGenomics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$7.62M.
  • NeoGenomics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$8.56M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$1.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28
-$2.60M
10-Q · filed 2026-07-28
-$3.83M
derived: sum of 3 quarters · filed 2026-07-28
-$4.63M
derived: sum of 4 quarters · filed 2026-07-28
2026-03-31-$1.30M
10-Q · filed 2026-04-28
-$2.53M
derived: sum of 2 quarters · filed 2026-04-28
-$3.33M
derived: sum of 3 quarters · filed 2026-04-28
-$2.42M
derived: sum of 4 quarters · filed 2026-07-28
2025-12-31-$1.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
-$2.03M
derived: sum of 2 quarters · filed 2026-02-17
-$1.13M
derived: sum of 3 quarters · filed 2026-07-28
-$2.21M
10-K · filed 2026-02-17
2025-09-30-$795.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$108.00K
derived: sum of 2 quarters · filed 2026-07-28
-$982.00K
10-Q · filed 2025-10-28
-$2.69M
derived: sum of 4 quarters · filed 2026-07-28
2025-06-30$903.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28
-$187.00K
10-Q · filed 2026-07-28
-$1.90M
derived: sum of 3 quarters · filed 2026-07-28
-$2.88M
derived: sum of 4 quarters · filed 2026-07-28
2025-03-31-$1.09M
10-Q · filed 2026-04-28
-$2.80M
derived: sum of 2 quarters · filed 2026-04-28
-$3.78M
derived: sum of 3 quarters · filed 2026-04-28
-$5.66M
derived: sum of 4 quarters · filed 2026-04-28
2024-12-31-$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
-$2.69M
derived: sum of 2 quarters · filed 2026-02-17
-$4.57M
derived: sum of 3 quarters · filed 2026-02-17
-$6.00M
10-K · filed 2026-02-17
2024-09-30-$979.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
-$2.85M
derived: sum of 2 quarters · filed 2025-10-28
-$4.29M
10-Q · filed 2025-10-28
-$6.04M
derived: sum of 4 quarters · filed 2026-02-17
2024-06-30-$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29
-$3.31M
10-Q · filed 2025-07-29
-$5.06M
derived: sum of 3 quarters · filed 2026-02-17
-$7.64M
derived: sum of 4 quarters · filed 2026-02-17
2024-03-31-$1.43M
10-Q · filed 2025-04-29
-$3.18M
derived: sum of 2 quarters · filed 2026-02-17
-$5.76M
derived: sum of 3 quarters · filed 2026-02-17
-$7.33M
derived: sum of 4 quarters · filed 2026-02-17
2023-12-31-$1.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
-$4.33M
derived: sum of 2 quarters · filed 2026-02-17
-$5.90M
derived: sum of 3 quarters · filed 2026-02-17
-$7.62M
10-K · filed 2026-02-17
2023-09-30-$2.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
-$4.15M
derived: sum of 2 quarters · filed 2024-11-05
-$5.87M
10-Q · filed 2024-11-05
-$7.34M
derived: sum of 4 quarters · filed 2025-02-18
2023-06-30-$1.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30
-$3.29M
10-Q · filed 2024-07-30
-$4.76M
derived: sum of 3 quarters · filed 2025-02-18
-$6.92M
derived: sum of 4 quarters · filed 2025-02-18
2023-03-31-$1.72M
10-Q · filed 2024-04-30
-$3.19M
derived: sum of 2 quarters · filed 2025-02-18
-$5.35M
derived: sum of 3 quarters · filed 2025-02-18
-$7.45M
derived: sum of 4 quarters · filed 2025-02-18
2022-12-31-$1.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
-$3.63M
derived: sum of 2 quarters · filed 2025-02-18
-$5.72M
derived: sum of 3 quarters · filed 2025-02-18
-$8.56M
10-K · filed 2025-02-18
2022-09-30-$2.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
-$4.25M
derived: sum of 2 quarters · filed 2023-11-06
-$7.09M
10-Q · filed 2023-11-06
2022-06-30-$2.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$4.93M
10-Q · filed 2023-08-08
2022-03-31-$2.83M
10-Q · filed 2023-05-09
2021-12-31-$7.88M
10-K · filed 2024-02-20
2020-12-31-$4.92M
10-K · filed 2023-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B